CapsoVision Inc

CapsoVision Inc(CV)股票分析

$6.990

+0.195 (+2.79%)收盘时

Loading chart…
最高
7.180
开盘
6.720
成交量加权均价
6.94
成交量
320.23K
市值
—
最低
6.660
成交额
2.22M
企业价值/息税折旧摊销前利润(TTM)
-8.69

CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule.

AI 分析 of CapsoVision Inc (CV)

买入

CapsoVision Inc is a good buy right now due to its recent FDA clearance for an AI-assisted tool, which could enhance its market position, and a 10% revenue growth in Q2 2026. The current price is $6.99, and the RSI is at 74.861, indicating strong momentum. However, the main risk is the negative net income of -7,481,000 USD reported in Q2 2026, which investors should consider.

估值指标

CapsoVision Inc(CV)当前预期市盈率为 0.00,5 年平均预期市盈率为 -10.86。

预期市盈率

高估
5 年均值 P/E
-10.86
当前P/E
0.00
高估
-5.23
低估
-16.50

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-6.42
当前EV/EBITDA
-8.69
高估
-1.29
低估
-11.56

预期市销率

合理
5 年均值 P/S
13.42
当前P/S
18.25
高估
20.16
低估
6.69

Alphio AI 对 CV 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%CV

$5.79

情景价格

基

基准

基准 · 50%CV

$5.05

情景价格

悲

悲观

悲观 · 25%CV

$4.89

情景价格

事件时间线

2026-09-28 (ET)

09:30:00

CapsoVision's AI Highlights Receives FDA Clearance

2026-08-27 (ET)

16:30:00

Outlook Therapeutics Appoints Kevin Lundquist as CFO

2026-08-13 (ET)

17:00:00

CapsoVision Files $250M Mixed Securities Shelf

2026-04-17 (ET)

16:40:00

CapsoVision Files to Sell 2.87M Shares of Common Stock

2026-03-23 (ET)

11:30:00

CapsoVision Closes $14M Private Placement Financing

资讯

CV 常见问题 —— 由 Alphio AI 解答

CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule. It operates in the Healthcare sector.

CapsoVision Inc is a good buy right now due to its recent FDA clearance for an AI-assisted tool, which could enhance its market position, and a 10% revenue growth in Q2 2026. The current price is $6.99, and the RSI is at 74.861, indicating strong momentum. However, the main risk is the negative net income of -7,481,000 USD reported in Q2 2026, which investors should consider.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易